Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -51.92 Million USD | -52.24% |
| 2022 | -34.1 Million USD | -36.61% |
| 2021 | -24.96 Million USD | -11.48% |
| 2020 | -22.39 Million USD | -1.46% |
| 2019 | -22.07 Million USD | 7.37% |
| 2018 | -23.82 Million USD | 11.46% |
| 2017 | -26.91 Million USD | -0.24% |
| 2016 | -26.84 Million USD | -8.13% |
| 2015 | -24.82 Million USD | -10.45% |
| 2014 | -22.48 Million USD | -241.03% |
| 2013 | -6.59 Million USD | 17.05% |
| 2012 | -7.94 Million USD | -79756.29% |
| 2011 | -9952.00 USD | 61.8% |
| 2010 | -26.05 Thousand USD | -62.58% |
| 2009 | -16.02 Thousand USD | 39.34% |
| 2008 | -26.41 Thousand USD | -120.29% |
| 2007 | -11.99 Thousand USD | 31.6% |
| 2006 | -17.53 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -12.41 Million USD | -29.39% |
| 2024 Q1 | -9.59 Million USD | 7.21% |
| 2023 FY | -51.92 Million USD | -52.24% |
| 2023 Q3 | -14.35 Million USD | 8.25% |
| 2023 Q2 | -15.64 Million USD | -35.03% |
| 2023 Q1 | -11.58 Million USD | -2.59% |
| 2023 Q4 | -10.34 Million USD | 27.93% |
| 2022 Q3 | -9.79 Million USD | -24.83% |
| 2022 FY | -34.1 Million USD | -36.61% |
| 2022 Q1 | -5.16 Million USD | 35.83% |
| 2022 Q2 | -7.85 Million USD | -52.01% |
| 2022 Q4 | -11.29 Million USD | -15.23% |
| 2021 Q2 | -5.07 Million USD | 5.53% |
| 2021 Q4 | -8.04 Million USD | -24.41% |
| 2021 FY | -24.96 Million USD | -11.48% |
| 2021 Q1 | -5.37 Million USD | 16.52% |
| 2021 Q3 | -6.46 Million USD | -27.47% |
| 2020 Q3 | -5.61 Million USD | -20.4% |
| 2020 FY | -22.39 Million USD | -1.46% |
| 2020 Q2 | -4.66 Million USD | 17.97% |
| 2020 Q1 | -5.68 Million USD | -22.65% |
| 2020 Q4 | -6.43 Million USD | -14.64% |
| 2019 Q1 | -5.69 Million USD | 10.44% |
| 2019 FY | -22.07 Million USD | 7.37% |
| 2019 Q2 | -5.08 Million USD | 10.76% |
| 2019 Q3 | -6.65 Million USD | -30.79% |
| 2019 Q4 | -4.63 Million USD | 30.35% |
| 2018 Q3 | -6.19 Million USD | -26.14% |
| 2018 FY | -23.82 Million USD | 11.46% |
| 2018 Q1 | -6.35 Million USD | -22.03% |
| 2018 Q2 | -4.91 Million USD | 22.68% |
| 2018 Q4 | -6.36 Million USD | -2.68% |
| 2017 FY | -26.91 Million USD | -0.24% |
| 2017 Q4 | -5.2 Million USD | 22.23% |
| 2017 Q3 | -6.69 Million USD | 7.06% |
| 2017 Q2 | -7.2 Million USD | 7.72% |
| 2017 Q1 | -7.8 Million USD | -14.34% |
| 2016 Q4 | -6.82 Million USD | 3.86% |
| 2016 Q2 | -6.91 Million USD | -15.26% |
| 2016 Q3 | -7.1 Million USD | -2.64% |
| 2016 Q1 | -6 Million USD | -21.99% |
| 2016 FY | -26.84 Million USD | -8.13% |
| 2015 FY | -24.82 Million USD | -10.45% |
| 2015 Q4 | -4.91 Million USD | -6.04% |
| 2015 Q3 | -4.63 Million USD | 37.34% |
| 2015 Q2 | -7.4 Million USD | 5.86% |
| 2015 Q1 | -7.86 Million USD | -14.45% |
| 2014 Q4 | -6.87 Million USD | 2.45% |
| 2014 FY | -22.48 Million USD | -241.03% |
| 2014 Q1 | -4.13 Million USD | -178.81% |
| 2014 Q2 | -4.42 Million USD | -6.92% |
| 2014 Q3 | -7.04 Million USD | -59.22% |
| 2013 Q1 | -2.02 Million USD | 74.5% |
| 2013 Q2 | -1.47 Million USD | 27.06% |
| 2013 Q3 | -1.6 Million USD | -9.04% |
| 2013 Q4 | -1.48 Million USD | 7.75% |
| 2013 FY | -6.59 Million USD | 17.05% |
| 2012 FY | -7.94 Million USD | -79756.29% |
| 2012 Q1 | -8416.00 USD | -468.26% |
| 2012 Q3 | -2.39 Million USD | -185.87% |
| 2012 Q4 | -7.93 Million USD | -230.56% |
| 2012 Q2 | -839.33 Thousand USD | -9873.13% |
| 2011 FY | -9952.00 USD | 61.8% |
| 2011 Q1 | -2680.00 USD | 62.96% |
| 2011 Q2 | -3361.00 USD | -25.41% |
| 2011 Q3 | -2430.00 USD | 27.7% |
| 2011 Q4 | -1481.00 USD | 39.05% |
| 2010 Q1 | -6537.00 USD | 16.24% |
| 2010 Q4 | -7235.00 USD | 10.94% |
| 2010 Q3 | -8124.00 USD | -95.43% |
| 2010 FY | -26.05 Thousand USD | -62.58% |
| 2010 Q2 | -4157.00 USD | 36.41% |
| 2009 Q3 | -2232.00 USD | -5.73% |
| 2009 Q1 | -3878.00 USD | 38.6% |
| 2009 FY | -16.02 Thousand USD | 39.34% |
| 2009 Q4 | -7804.00 USD | -249.64% |
| 2009 Q2 | -2111.00 USD | 45.56% |
| 2008 Q1 | -9705.00 USD | -115.67% |
| 2008 Q2 | -8304.00 USD | 14.44% |
| 2008 Q3 | -2094.00 USD | 74.78% |
| 2008 Q4 | -6316.00 USD | -201.62% |
| 2008 FY | -26.41 Thousand USD | -120.29% |
| 2007 Q3 | -4653.00 USD | -63.84% |
| 2007 Q2 | -2840.00 USD | -552.87% |
| 2007 FY | -11.99 Thousand USD | 31.6% |
| 2007 Q1 | -435.00 USD | 94.2% |
| 2007 Q4 | -4500.00 USD | 3.29% |
| 2006 Q3 | -10.03 Thousand USD | 0.0% |
| 2006 Q4 | -7504.00 USD | 25.18% |
| 2006 FY | -17.53 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | -62.677% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -445.493% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | -26.975% |
| Azitra, Inc. | -7.61 Million USD | -581.687% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -533.557% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -656.599% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | -79.084% |
| CEL-SCI Corporation | -31.47 Million USD | -64.951% |
| iBio, Inc. | -16.63 Million USD | -212.132% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -109.922% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -157.254% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -118.463% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -269.514% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -937.777% |
| NanoViricides, Inc. | -8.51 Million USD | -509.668% |
| Oragenics, Inc. | -20.9 Million USD | -148.363% |
| BiomX Inc. | -27.68 Million USD | -87.538% |
| BiomX Inc. | -27.68 Million USD | -87.538% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 596.367% |
| Palatin Technologies, Inc. | -22.49 Million USD | -130.795% |
| Scorpius Holdings, Inc. | -42.03 Million USD | -23.524% |